The DOI matches its Crossref record; 233 of the 233 references it cites were found in a registry or an index.
Endothelial dysfunction — A major mediator of diabetic vascular disease
Open accessAbstract
The vascular endothelium is a multifunctional organ and is critically involved in modulating vascular tone and structure. Endothelial cells produce a wide range of factors that also regulate cellular adhesion, thromboresistance, smooth muscle cell proliferation, and vessel wall inflammation. Thus, endothelial function is important for the homeostasis of the body and its dysfunction is associated with several pathophysiological conditions, including atherosclerosis, hypertension and diabetes. Patients with diabetes invariably show an impairment of endothelium-dependent vasodilation. Therefore, understanding and treating endothelial dysfunction is a major focus in the prevention of vascular complications associated with all forms of diabetes mellitus. The mechanisms of endothelial dysfunction in diabetes may point to new management strategies for the prevention of cardiovascular disease in diabetes. This review will focus on the mechanisms and therapeutics that specifically target endothelial dysfunction in the context of a diabetic setting. Mechanisms including altered glucose metabolism, impaired insulin signaling, low-grade inflammatory state, and increased reactive oxygen species generation will be discussed. The importance of developing new pharmacological approaches that upregulate endothelium-derived nitric oxide synthesis and target key vascular ROS-producing enzymes will be highlighted and new strategies that might prove clinically relevant in preventing the development and/or retarding the progression of diabetes associated vascular complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–233 of 233
Kang, K.-T., Sullivan, J. C., Sasser, J. M., Imig, J. D., & Pollock, J. S. (2007) · Hypertension · doi:10.1161/01.hyp.0000259669.40991.1e · Cited by 57
Bucci, M., Roviezzo, F., Brancaleone, V., Lin, M. I., Lorenzo, A. D., Cicala, C., Pinto, A., Sessa, W. C., Farneti, S., Fiorucci, S., et al. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000122362.44628.09 · Cited by 56
Guns, P., Assche, T. V., Verreth, W., Fransen, P. F., Mackness, B., Mackness, M., Holvoet, P., & Bult, H. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707585 · Cited by 55
Lanati, N., Emanuele, E., Brondino, N., & Geroldi, D. (2010) · Current Vascular Pharmacology · doi:10.2174/157016110790226642 · Cited by 54
Wang, X., Huang, J., Zou, J., Su, E., Shan, Q., Yang, Z., & Cao, K. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04667.x · Cited by 53
Radovits, T., Seres, L., Gerő, D., Lin, L., Beller, C. J., CHEN, S., Zotkina, J., Berger, I., Groves, J. T., & Szabó, C. (2006) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.09.005 · Cited by 53
Hypoglycemic pharmacological treatment of type 2 diabetes: Targeting the endothelium
Nathanson, D., & Nyström, T. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.11.016 · Cited by 53
Eicosanoids and the Vascular Endothelium
Egan, K. M., & FitzGerald, G. A. (2006) · Springer eBooks · doi:10.1007/3-540-32967-6_6 · Cited by 52
Resveratrol: A Multifunctional Compound Improving Endothelial Function
Li, H., & Förstermann, U. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-009-6209-0 · Cited by 51
Point: Postprandial Glucose Levels Are a Clinically Important Treatment Target
Ceriello, A. (2010) · Diabetes Care · doi:10.2337/dc10-0634 · Cited by 51
Oxidant-Redox Regulation of Pulmonary Vascular Responses to Hypoxia and Nitric Oxide-cGMP Signaling
Wolin, M. S., Gupte, S. A., Neo, B. H., Gao, Q., & Ahmad, M. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181c9f088 · Cited by 49
Protective role of heme oxygenase in the blood vessel wall during atherogenesis
Hoekstra, K. A., Godin, D. V., & Cheng, K. M. (2004) · Biochemistry and Cell Biology · doi:10.1139/o04-006 · Cited by 49
Söylemez, S., Sepici, A., & Akar, F. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-009-6198-z · Cited by 49
Red Wine and Cardiovascular Health
Li, H., & Förstermann, U. (2012) · Circulation Research · doi:10.1161/circresaha.112.278705 · Cited by 49
Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunction
de Haan, J. B., & Cooper, M. E. (2010) · Frontiers in Bioscience-Scholar · doi:10.2741/s182 · Cited by 47
eNOS phosphorylation on serine 1176 affects insulin sensitivity and adiposity
Kashiwagi, S., Atochin, D. N., Li, Q., Schleicher, M., Pong, T., Sessa, W. C., & Huang, P. L. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.110 · Cited by 47
Bräsen, J. H., Leppänen, O., Inkala, M., Heikura, T., Levin, M., Ahrens, F., Rutanen, J., Pietsch, H., Bergqvist, D., Levonen, A., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.08.038 · Cited by 46
Dessy, C., Féron, O., & Balligand, J. (2010) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-010-0815-3 · Cited by 43
Blockade of PKC-beta protects HUVEC from advanced glycation end products induced inflammation
Xu, Y., Wang, S., Feng, L., Zhu, Q., Xiang, P., & He, B. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.09.006 · Cited by 42
Gene Therapy Targeting Inflammation in Atherosclerosis
Van-Assche, T., Huygelen, V., Crabtree, M. J., & Antoniades, C. A. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798764799 · Cited by 41
Ramprasath, T., Kumar, P. H., Puhari, S. S. M., Murugan, P. S., Vasudevan, V., & Selvam, G. S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.10.064 · Cited by 39
Irvine, J. C., Kemp‐Harper, B. K., & Widdop, R. E. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3269 · Cited by 38
Novel Insights into the Vasoprotective Role of Heme Oxygenase‐1
Marcantoni, E., Francesco, L. D., Dovizio, M., Bruno, A., & Patrignani, P. (2012) · International Journal of Hypertension · doi:10.1155/2012/127910 · Cited by 31
Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics
Highlander, P. D., & Shaw, G. P. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709354305 · Cited by 30
Cloarec, M., Caillard, P., Provost, J.-C., et al. (2007) · PubMed · Cited by 26
Tetrahydrobiopterin: A Vascular Redox Target to Improve Endothelial Function
Channon, K. M. (2012) · Current Vascular Pharmacology · doi:10.2174/157016112803520819 · Cited by 24
Mindrescu, C., Gupta, R. P., Hermance, E. V., DeVoe, M. C., Soma, V. R., Coppola, J. T., & Staniloae, C. S. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4001 · Cited by 21
Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Hoenicka, M., & Schmid, Ç. (2008) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152508785909555 · Cited by 21
Review: Endothelial cell dysfunction, medial arterial calcification and osteoprotegerin in diabetes
Singh, D. K., Winocour, P. H., & Farrington, K. (2010) · The British Journal of Diabetes · doi:10.1177/1474651409355453 · Cited by 20
Lp-PLA2 as a Marker of Cardiovascular Diseases
Bhatti, S., Hakeem, A., & Çilingiroğlu, M. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0095-6 · Cited by 16
Linking diabetes and atherosclerosis
Candido, R., Bernardi, S., & Allen, T. J. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.46 · Cited by 13
Symons, J. D. (2013) · Diabetes · doi:10.2337/db13-0255 · Cited by 10
English, F. A., McCarthy, F. P., Andersson, I. J., Stanley, J. L., Davidge, S. T., Baker, P. N., Walsh, S. K., & Kenny, L. C. (2012) · Reproductive Sciences · doi:10.1177/1933719111433885 · Cited by 7
Cited by
Pathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
“AGE binding to the RAGE-receptor, nuclear transcription factor NF-κB [242,243] is activated leading to transcription of endothelin-1, VCAM-1, ICAM-1, E-selectin, thrombomodulin, TF, vascular endothelial growth factor (VEGF), IL-1, IL-6, and TNF-α [242,244].”
BackgroundIncalza, M. A., D'Oria, R., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.05.005 · Cited by 1,356
MCP-1: Function, regulation, and involvement in disease
Singh, S., Anshita, D., & Ravichandiran, V. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107598 · Cited by 883
Circular RNA and its mechanisms in disease: From the bench to the clinic
Han, B., Chao, J., & Yao, H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.010 · Cited by 788
González, P., Lozano, P., Ros, G., & Solano, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119352 · Cited by 777
Metadata
- Authors
- Sena, C. M., Pereira, A. M., & Seiça, R.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 1832
- Issue
- 12
- Pages
- 2216-2231
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W2069294586
- Cited by
- 797
- References
- 233
- FWCI
- 30.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.